The hypertriglyceridemic waist phenotype versus the National Cholesterol Education Program-Adult Treatment Panel III and International Diabetes Federation clinical criteria to identify high-risk men with an altered cardiometabolic risk profile

Metabolism: Clinical and Experimental

Volumn 58, Issue 8, 2009, Pages 1123-1130

  Blackburn, Patricia ^a,b,c   Lemieux, Isabelle ^b   Alméras, Natalie ^b   Bergeron, Jean ^d   Côté, Mélanie ^b   Tremblay, Angelo ^c   Lamarche, Benoît ^c,e   Després, Jean Pierre ^b,c  

^a UNIVERSITÉ DU QUÉBEC À CHICOUTIMI   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d LAVAL UNIVERSITY   (Canada)

^e LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN B; C REACTIVE PROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; HIGH RISK POPULATION; HUMAN; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SCORING SYSTEM; SCREENING TEST; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADIPONECTIN; ADULT; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; PHENOTYPE; RISK ASSESSMENT; RISK FACTORS; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 67651089993     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.03.012     Document Type: Article

References (51)

1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
2. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
3. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
4. Scuteri A., Najjar S.S., Morrell C.H., et al. The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study. Diabetes Care 28 (2005) 882-887
5. Després J.P., and Lemieux I. Abdominal obesity and metabolic syndrome. Nature 444 (2006) 881-887
6. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
7. De Backer G., Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 24 (2003) 1601-1610
8. Alberti K.G., Zimmet P., and Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 366 (2005) 1059-1062
9. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
10. Balkau B., and Charles M.A. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16 (1999) 442-443
11. Grundy S.M., Brewer H.B., Cleeman J.I., et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 (2004) 433-438
12. Lemieux I., Pascot A., Couillard C., et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?. Circulation 102 (2000) 179-184
13. Després J.P., Lemieux I., Bergeron J., et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 28 (2008) 1039-1049
14. Katzmarzyk P.T., Janssen I., Ross R., et al. The importance of waist circumference in the definition of metabolic syndrome: prospective analyses of mortality in men. Diabetes Care 29 (2006) 404-409
15. Lemieux I., Alméras N., Mauriège P., et al. Prevalence of "hypertriglyceridemic waist" in men who participated in the Quebec Health Survey: association with atherogenic and diabetogenic metabolic risk factors. Can J Cardiol 18 (2002) 725-732
16. Tankó L.B., Bagger Y.Z., Qin G., et al. Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation 111 (2005) 1883-1890
17. Lohman T.G., Roche A.F., and Martorell R. Anthropometric standardization reference manual (1988), Human Kinetics, Champaign (Ill)
18. van der Kooy K., and Seidell J.C. Techniques for the measurement of visceral fat: a practical guide. Int J Obes Relat Metab Disord 17 (1993) 187-196
19. Ferland M., Després J.P., Tremblay A., et al. Assessment of adipose tissue distribution by computed axial tomography in obese women: association with body density and anthropometric measurements. Br J Nutr 61 (1989) 139-148
20. Fossati P., and Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 28 (1982) 2077-2080
21. Allain C.C., Poon L.S., Chan C.S.G., et al. Enzymatic determination of total serum cholesterol. Clin Chem 20 (1974) 470-475
22. Burstein M., and Samaille J. Sur un dosage rapide du cholestérol lié aux beta-lipoprotéines du sérum. Clin Chim Acta 5 (1960) 609-610
23. Laurell C.B. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 15 (1966) 45-52
24. Moorjani S., Dupont A., Labrie F., et al. Increase in plasma high density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism 36 (1987) 244-250
25. Tchernof A., Lamarche B., Prud'homme D., et al. The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 19 (1996) 629-637
26. Richterich R., and Dauwalder H. Determination of plasma glucose by hexokinase-glucose-6-phosphate dehydrogenase method. Schweiz Med Wochenschr 101 (1971) 615-618
27. Desbuquois B., and Aurbach G.D. Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays. J Clin Endocrinol Metab 37 (1971) 732-738
28. Ledue T.B., Weiner D.L., Sipe J.D., et al. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 35 (1998) 745-753
29. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
30. Malik S., Wong N.D., Franklin S.S., et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110 (2004) 1245-1250
31. Dekker J.M., Girman C., Rhodes T., et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 112 (2005) 666-673
32. Hanley A.J., Karter A.J., Williams K., et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation 112 (2005) 3713-3721
33. Ford E.S., Giles W.H., and Mokdad A.H. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 27 (2004) 2444-2449
34. Kahn H.S., and Valdez R. Metabolic risks identified by the combination of enlarged waist and elevated triacylglycerol concentration. Am J Clin Nutr 78 (2003) 928-934
35. Solati M., Ghanbarian A., Rahmani M., et al. Cardiovascular risk factors in males with hypertriglycemic waist (Tehran Lipid and Glucose Study). Int J Obes Relat Metab Disord 28 (2004) 706-709
36. LaMonte M.J., Ainsworth B.E., DuBose K.D., et al. The hypertriglyceridemic waist phenotype among women. Atherosclerosis 171 (2003) 123-130
37. Hiura Y., Acklin F., Newman J., et al. Hypertriglyceridemic waist as a screening tool for CVD risk in indigenous Australian women. Ethn Dis 13 (2003) 80-84
38. Blackburn P., Lamarche B., Couillard C., et al. Postprandial hyperlipidemia: another correlate of the "hypertriglyceridemic waist" phenotype in men. Atherosclerosis 171 (2003) 327-336
39. Esmaillzadeh A., Mirmiran P., and Azizi F. Clustering of metabolic abnormalities in adolescents with the hypertriglyceridemic waist phenotype. Am J Clin Nutr 83 (2006) 36-46 [quiz 183-4]
40. Senechal M., Lemieux I., Beucler I., et al. Features of the metabolic syndrome of "hypertriglyceridemic waist" and transplant coronary artery disease. J Heart Lung Transplant 24 (2005) 819-826
41. Bos G., Dekker J.M., and Heine R.J. Non-HDL cholesterol contributes to the "hypertriglyceridemic waist" as a cardiovascular risk factor: the Hoorn study. Diabetes Care 27 (2004) 283-284
42. Correll C.U., Frederickson A.M., Kane J.M., et al. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 67 (2006) 575-583
43. Czernichow S., Bruckert E., Bertrais S., et al. Hypertriglyceridemic waist and 7.5-year prospective risk of cardiovascular disease in asymptomatic middle-aged men. Int J Obes (Lond) 31 (2007) 791-796
44. Pollex R.L., Hanley A.J., Zinman B., et al. Clinical and genetic associations with hypertriglyceridemic waist in a Canadian aboriginal population. Int J Obes (Lond) 30 (2006) 484-491
45. Gazi I.F., Filippatos T.D., Tsimihodimos V., et al. The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. Lipids 41 (2006) 647-654
46. Després J.P., Lamarche B., Mauriège P., et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334 (1996) 952-957
47. Lamarche B., Tchernof A., Mauriège P., et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 279 (1998) 1955-1961
48. Lamarche B., Moorjani S., Lupien P.J., et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 94 (1996) 273-278
49. Motoshima H., Wu X., Sinha M.K., et al. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab 87 (2002) 5662-5667
50. Matsuzawa Y., Funahashi T., Kihara S., et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24 (2004) 29-33
51. Ford E.S., Mokdad A.H., and Giles W.H. Trends in waist circumference among US adults. Obes Res 11 (2003) 1223-1231